Physician profile
Hansen A Yuan
NPI 1992797013
$31,720,255.40
in general payments reported to CMS, 2019-2025
5 companies · $52K in 2025
The $52K reported for 2025 was more than what 88% of Orthopaedic Surgery of The Spine providers received nationally (typical 2025 total: $2,116).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $31M · 2020: $127K · 2021: $97K · 2022: $84K · 2023: $74K · 2024: $45K · 2025: $52K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Royalty Or License: $171K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Royalty Or License | $171,113.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $31,667,414.31 | 2019-2025 | Radius |
| Vb Spine LLC | $41,961.28 | 2025 | Xia 3 |
| Surgalign Spine Technologies, INC. | $10,196.35 | 2019-2022 | |
| Integrity Implants INC. | $683.46 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$45,166.72 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hansen Yuan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.